Marksans Pharma reported a strong set of quarterly earnings for the March 2026 quarter, driven by healthy revenue growth and significant improvement in operating profitability.
The company’s consolidated revenue from operations for Q4FY26 stood at ₹856.11 crore, rising from ₹708.46 crore reported in the corresponding quarter last year.
Based on the reported financials, EBITDA for the quarter came in at ₹195.42 crore compared with ₹126.94 crore in Q4FY25. EBITDA margin expanded sharply to 22.8% from 17.9% a year ago.
Profit after tax for the quarter stood at ₹149.03 crore, registering strong growth from ₹90.73 crore reported in the corresponding period last year.
Total income during the quarter rose to ₹891.29 crore from ₹723.80 crore in Q4FY25.
The company reported total expenses of ₹691.29 crore during the quarter compared with ₹607.70 crore a year earlier. Employee benefit expenses increased to ₹106.76 crore from ₹97.22 crore, while other expenses rose to ₹163.28 crore from ₹159.08 crore in the corresponding quarter last year.
Finance costs during the quarter stood at ₹6.31 crore compared with ₹3.44 crore reported a year ago. Depreciation and amortisation expenses increased to ₹24.29 crore from ₹22.74 crore in Q4FY25.
Profit before tax came in at ₹200 crore during Q4FY26, significantly higher than ₹116.09 crore reported in the year-ago quarter.
Sequentially too, the company reported improvement in profitability. PAT rose from ₹113.69 crore in Q3FY26 to ₹149.03 crore in Q4FY26, while revenue from operations increased from ₹754.43 crore to ₹856.11 crore.
The company also reported total comprehensive income of ₹202.97 crore during the quarter compared with ₹117.21 crore in Q4FY25, aided by foreign currency translation gains.
The strong quarterly performance reflects continued momentum in the company’s formulations business along with improved operating leverage and margin expansion.
Disclaimer: This article is based on company filings and publicly available financial disclosures. Investors are advised to consult certified financial advisors before making investment decisions.